Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Camidge DR, et al. Among authors: kim dw, kim hr. N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280657 Free article. Clinical Trial.
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, Ha SJ, Soo RA, Chung KY, Kim JH, Lee JH, Shim HS, Cho BC. Kim HR, et al. Among authors: kim sh, kim dj, kim jh. J Clin Oncol. 2013 Feb 20;31(6):731-7. doi: 10.1200/JCO.2012.43.8622. Epub 2012 Nov 26. J Clin Oncol. 2013. PMID: 23182986
Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer.
Lim S, Cho BC, Jung JY, Kim GM, Kim SH, Kim HR, Kim HS, Lim SM, Park JS, Lee JH, Kim D, Kim EY, Park MS, Kim YS, Kim SK, Chang J, Kim JH. Lim S, et al. Among authors: kim ey, kim sh, kim d, kim gm, kim sk, kim hr, kim ys, kim hs, kim jh. Lung Cancer. 2013 Jun;80(3):313-8. doi: 10.1016/j.lungcan.2013.02.009. Epub 2013 Mar 16. Lung Cancer. 2013. PMID: 23510628 Clinical Trial.
Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor.
Jeong JH, Cho BC, Shim HS, Kim HR, Lim SM, Kim SK, Chung KY, Ul Islam SM, Song JJ, Kim SY, Kim JH. Jeong JH, et al. Among authors: kim sy, kim sk, kim hr, kim jh. J Korean Med Sci. 2013 Jul;28(7):1005-14. doi: 10.3346/jkms.2013.28.7.1005. Epub 2013 Jul 3. J Korean Med Sci. 2013. PMID: 23853482 Free PMC article.
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: kim sb, kim b, kim sh, kim tm, kim hr, kim jh. Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424851 Clinical Trial.
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, Lee YC, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: kim hg, kim h, kim dj, kim sm, kim hr, kim jh. Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056. Oncotarget. 2015. PMID: 26462025 Free PMC article. Clinical Trial.
3,227 results